ArticleBioMed research international2022
Respiratory Care of Big Data Communication to Prevent Respiratory Tract Infection Nursing Analysis of Patients with Heart Failure.
Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Study on the clinical efficacy, safety and compliance of quality nursing intervention in the treatment of chronic heart failure combined with respiratory tract infections.Pakistan journal of medical sciences · 2024Article
- Retracted: Respiratory Care of Big Data Communication to Prevent Respiratory Tract Infection Nursing Analysis of Patients with Heart Failure.BioMed research international · 2023Article
Corrections and comments
- Retraction · 2023-07-12Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Informed/Patient Consent - None/Withdrawn · Investigation by Journal/Publisher · Investigation by Third Party · Lack of IRB/IACUC Approval and/or Compliance · Computer-Aided Content or Computer-Generated Content · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is the final stage of the development of heart disease, with a high mortality and disability rate. It poses a serious threat to human health and brings tremendous pressure to human society. Preventing respiratory infections in patients with heart failure is also the first priority of care. This article is aimed at studying the nursing analysis of respiratory tract care based on big data exchanges to prevent respiratory tract infections in patients with heart failure. This article uses benchmark and sample collection. Studies have shown that for Pseudomonas aeruginosa, its resistance to ampicillin, amoxicillin/clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefotaxime, and cefoxitin has reached more than 80%. It is also suitable for piperacillin, ticarcillin/clavulanic acid, piperacillin/tazobactam, cefepime, aztreonam, gentamicin, tobramycin, ciprofloxacin, and levofloxacin. The resistance rate of stars is within 10%-30%. These antibiotics are effective and can be used for clinical treatment. The drug resistance rates of ceftazidime, imipenem, meropenem, and amikacin were all lower than 10%, and the drug resistance rates of ceftazidime and imipenem were much lower than those reported in the 2016 literature. These antibiotics have become the most effective drugs for the treatment of Pseudomonas aeruginosa infections. Basically, good communication of respiratory care data is realized, thereby preventing respiratory care analysis of patients with heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.